Gbx International Group Stock Price, News & Analysis
GBXI
OTC
Company Description
GBX International Group, Inc. (OTC PINK: GBXI) is a prominent player in international economic development, focusing on innovative cancer drug research and development. The company is currently raising $1 million for critical operating capital to accelerate cancer drug valuation audits, drug releases, and uplisting to NASDAQ. With a portfolio of low-cost, effective cancer-killing drugs, including the Harvard Award-Winning CSi-Harvard, GBXI aims to revolutionize cancer treatment accessibility and affordability.
Stock Performance
$—
0.00%
0.00
Last updated:
- %
Performance 1 year
$14.1K
Market Cap
140.9M
Shares outstanding
Latest News
SEC Filings
No SEC filings available for Gbx International Group.
Financial Highlights
—
Revenue (TTM)
—
Net Income (TTM)
—
Diluted EPS (TTM)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin
Upcoming Events
Frequently Asked Questions
What is the current stock price of Gbx International Group (GBXI)?
The current stock price of Gbx International Group (GBXI) is $0.0001 as of June 10, 2025.
What is the market cap of Gbx International Group (GBXI)?
The market cap of Gbx International Group (GBXI) is approximately 14.1K.
What is GBX International Group, Inc. (GBXI) known for?
GBXI is known for its international economic development initiatives, particularly in the field of cancer drug research and development.
What is the current financial focus of GBXI?
GBXI is currently raising $1 million for critical operating capital to accelerate cancer drug valuation audits, drug releases, and NASDAQ uplisting.
What sets GBXI's cancer-killing drugs apart?
GBXI's portfolio includes low-cost, effective cancer-killing drugs, notably the Harvard Award-Winning CSi-Harvard drug, designed to make cancer treatment more accessible and affordable.
What are GBXI's plans for the future?
GBXI aims to revolutionize cancer treatment accessibility and affordability through its groundbreaking drug portfolio, strategic partnerships, and market uplisting.
How does GBXI impact the cancer treatment landscape?
GBXI's innovative approach to cancer drug research and development has the potential to transform the cancer treatment landscape, offering cost-effective solutions and hope to patients in need.
Who leads GBX International Group, Inc.?
Raymond C. Dabney serves as the President & CEO, Chancellor of GBXI, overseeing the company's strategic direction and growth initiatives.
What is the significance of GBXI's Harvard Award-Winning drugs?
GBXI's Harvard Award-Winning drugs, particularly the CSi-Harvard drug, have the potential to significantly impact the cancer treatment market by offering effective, low-cost alternatives to existing treatments.
How does GBXI aim to raise funds for its initiatives?
GBXI is actively raising capital to support its cancer drug research and development projects, including fundraising efforts to accelerate valuation audits, drug releases, and market uplisting.
What partnerships does GBXI have in the healthcare industry?
GBXI collaborates with various stakeholders in the healthcare industry to advance its cancer drug research and development efforts, with a focus on creating innovative, cost-effective solutions for patients worldwide.
What is the long-term vision of GBX International Group, Inc.?
GBXI's long-term vision is to become a leading player in the international economic development sector, particularly in the field of cancer drug research and development, by offering groundbreaking drugs that revolutionize cancer treatment accessibility and affordability.